Growth Differentiation Factor 15 (GDF15) is an stress-responsive cytokine and member of the transforming growth factor-beta (TGF-β) superfamily.
Cellular Stress Signal: GDF15 is produced when cells experience mitochondrial dysfunction, DNA damage, oxidative stress, hypoxia, or inflammation.
Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine, also called macrophage inhibitory cytokine-1 (MIC-1), released with cellular injury, inflammation, oxidative or mitochondrial stress, hypoxia, and aging.
Brain-Body Axis: It circulates in the blood and binds to the GFRAL (GDNF family receptor alpha-like) receptor complex located in the hindbrain (area postrema).
Appetite & Weight Regulation: Activation of GFRAL by GDF15 suppresses appetite, reduces food intake, and triggers metabolic adaptations or nausea/emesis.
Elevated plasma GDF15 levels serve as a sensitive and specific biomarker used in the diagnostic workup for neuromuscular and mitochondrial myopathies.
GDF15 levels rise progressively with age as cellular stress accumulates, making it a prominent independent predictor of all-cause mortality, frailty, and biological aging.
Pathological Conditions:
High levels are frequently observed in chronic disease states, including cardiovascular disease, heart failure, type 2 diabetes, renal disease, pregnancy (abundant in the placenta), and hyperemesis gravidarum.
Cancer Cachexia: In advanced cancers, excessive GDF15 secretion drives severe weight loss, anorexia, and muscle wasting (cachexia).
Therapeutic antagonists (such as ponsegromab) are being investigated to block this pathway and reverse cachexia.
It is physiologically abundant in the placenta and rises markedly during pregnancy.
Elevated GDF-15 is nonspecific: elevations occur in heart failure, acute coronary syndromes, chronic kidney or liver disease, diabetes, inflammation, cancer, mitochondrial disorders, smoking, and older age.
Its best-established role is prognostic rather than diagnostic.
In an individual-patient meta-analysis of 53,486 patients with atherosclerotic cardiovascular disease, higher GDF-15 independently predicted cardiovascular death and hospitalization for heart failure; associations with myocardial infarction and stroke were less consistent during acute coronary syndrome.
It should not be used alone to diagnose myocardial infarction or cancer. It does not replace electrocardiography, high-sensitivity troponin, natriuretic peptides, imaging, or tissue diagnosis.
Biology: circulating GDF-15 acts through the glial cell-derived neurotrophic factor family receptor α-like (GFRAL)–RET pathway in the hindbrain, influencing appetite and energy balance; high levels are associated with anorexia and cachexia, particularly in advanced cancer.
Reference values are assay- and population-dependent.
An isolated high GDF-15 indicates systemic biological stress and increased risk, not a specific diagnosis. Interpretation should incorporate age, renal function, pregnancy status, symptoms, and targeted evaluation for cardiac, renal, inflammatory, metabolic, or malignant disease.